Indivior (INDV) Reaches New 12-Month Low at $93.24
Shares of Indivior PLC (LON:INDV) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as GBX 93.24 ($1.22) and last traded at GBX 93.66 ($1.22), with a volume of 2922987 shares trading hands. The stock had previously closed at GBX 102.10 ($1.33).
Several analysts recently issued reports on the stock. Royal Bank of Canada downgraded shares of Indivior to an “outperform” rating and reduced their price target for the company from GBX 350 ($4.57) to GBX 130 ($1.70) in a research report on Wednesday, November 21st. Citigroup restated a “neutral” rating on shares of Indivior in a research note on Monday, October 15th. Jefferies Financial Group dropped their price objective on Indivior from GBX 250 ($3.27) to GBX 245 ($3.20) and set a “buy” rating on the stock in a research note on Thursday, October 11th. Finally, Numis Securities restated a “buy” rating and set a GBX 350 ($4.57) price objective on shares of Indivior in a research note on Thursday, September 27th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of GBX 294.60 ($3.85).
ILLEGAL ACTIVITY NOTICE: “Indivior (INDV) Reaches New 12-Month Low at $93.24” was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/indivior-indv-reaches-new-12-month-low-at-93-24/2663241.html.
Indivior Company Profile (LON:INDV)
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Recommended Story: Terms to Better Understand Call Options
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.